Chardan Capital Reaffirms “Buy” Rating for Dyne Therapeutics (NASDAQ:DYN)
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $50.00 price objective on the stock. Chardan Capital’s price target would indicate a potential upside of 363.82% from the company’s previous close. Other […]
Dyne Therapeutics (NASDAQ:DYN – Get Free Report)‘s stock had its “buy” rating restated by Chardan Capital in a research report issued to clients and investors on Tuesday,Benzinga reports. They presently have a $50.00 price objective on the stock. Chardan Capital’s price target would indicate a potential upside of 363.82% from the company’s previous close. Other […]
